The estimated Net Worth of James A Schoeneck is at least 5.82 百万$ dollars as of 7 June 2023. Mr. Schoeneck owns over 7,100 units of FibroGen Inc stock worth over 29,489$ and over the last 10 years he sold FGEN stock worth over 128,013$. In addition, he makes 5,661,570$ as Chairman of the Board at FibroGen Inc.
James has made over 12 trades of the FibroGen Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 7,100 units of FGEN stock worth 128,013$ on 7 June 2023.
The largest trade he's ever made was exercising 24,000 units of FibroGen Inc stock on 30 October 2018 worth over 333,360$. On average, James trades about 2,472 units every 57 days since 2014. As of 7 June 2023 he still owns at least 73,722 units of FibroGen Inc stock.
You can see the complete history of Mr. Schoeneck stock trades at the bottom of the page.
James A. Schoeneck serves as Chairman of the Board of the Company. He has served on our board of directors since April 2010. Mr. Schoeneck was Chief Executive Officer of Depomed, Inc., a commercial specialty pharmaceutical company, from 2011 until 2017, and joined the Board of Depomed in 2007. In addition, from 2015 to 2018, Mr. Schoeneck served on the board of directors of AnaptysBio, Inc. From 2005 until 2011, he was Chief Executive Officer of BrainCells, Inc., a privately-held biopharmaceutical company. Prior to joining BrainCells, Inc., he served as Chief Executive Officer of ActivX BioSciences, Inc., a development-stage biotechnology company. Mr. Schoeneck’s pharmaceutical experience also includes three years as President and Chief Executive Officer of Prometheus Laboratories Inc., a pharmaceutical and diagnostics products company. Prior to joining Prometheus, Mr. Schoeneck spent three years as vice president and General Manager, Immunology, at Centocor, Inc. (now Janssen Biotech, Inc.), a biotechnology company, where he led the development of Centocor’s commercial capabilities. His group launched Remicade®, which became one of the world’s largest pharmaceutical brands. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi), a pharmaceutical company, serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck holds a Bachelor of Science degree in Education from Jacksonville State University.
As the Chairman of the Board of FibroGen Inc, the total compensation of James Schoeneck at FibroGen Inc is 5,661,570$. There are 1 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of 5,856,450$.
James Schoeneck is 62, he's been the Chairman of the Board of FibroGen Inc since 2020. There are 8 older and 13 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
James's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over 188,593,537$ worth of FibroGen Inc stock and bought 106,523 units worth 1,309,423$ . The most active insiders traders include Rory B Riggs、Thomas B Neff、Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 6,963$. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth 25,884$.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: